Weight Watchers Launches Wegovy Oral Medication at $149 Monthly Fee
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Source: Globenewswire
- Expanded Drug Access: Weight Watchers introduces Novo Nordisk's newly FDA-approved Wegovy oral medication through its GLP-1 platform, reinforcing its leadership in integrated care models that help users succeed with medication.
- Significant Outcomes: Members of Weight Watchers Med+ who engaged with the GLP-1 Success Program lost an average of 61.3% more body weight, demonstrating the effectiveness of combining behavioral support with medication, thereby enhancing customer satisfaction and loyalty.
- Clear Market Positioning: The launch of the Wegovy oral medication offers a more convenient option for patients hesitant about injectable therapies, with a monthly fee of $149 lowering the entry barrier and attracting more users seeking clinically supported weight management.
- Deepened Strategic Collaboration: Weight Watchers' partnership with Novo Nordisk aligns on education and drug access while ensuring ongoing support beyond prescriptions, further solidifying its market position in weight management.
Get Free Real-Time Notifications for Any Stock
Monitor tickers like WW with instant alerts to capture every critical market movement.
Sign up for free to build your custom watchlist and receive professional-grade stock notifications.
Analyst Views on WW
Wall Street analysts forecast WW stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for WW is 38.00 USD with a low forecast of 38.00 USD and a high forecast of 38.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
0 Buy
1 Hold
0 Sell
Hold
Current: 21.190
Low
38.00
Averages
38.00
High
38.00
Current: 21.190
Low
38.00
Averages
38.00
High
38.00
About WW
WW International, Inc. provides science-backed weight loss and weight management programs. The Company provides an accessible, holistic model of care through its doctor-recommended Points Program, clinical interventions including weight-loss medications, and community support. Its weight-loss and weight management programs are focused on nutritional and behavior change science. They are comprised of a range of science-based nutritional, activity, behavioral and lifestyle tools and approaches that can be tailored for individual weight goals and, if needed, support the various needs of people taking GLP-1 medications. Its offerings include Behavior Change Programs, WeightWatchers Clinic, Licensing and Consumer Product Sales. Its subscription businesses include digital business, workshops + digital business, clinical business and WeightWatchers for business offering nutritional and behavior change science. Its WW-branded products include bars, snacks, cookbooks and kitchen tools.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk's Oral Wegovy Hits Record 20,371 Prescriptions in Second Week, Nearly 500% Surge
- Prescription Surge: Novo Nordisk's oral Wegovy reached 20,371 prescriptions in its second week, a nearly 500% increase from 4,289 in the first week, indicating rapid market acceptance that could reshape revenue trajectories in the weight-loss drug market.
- Significant Market Potential: This figure is likely conservative as retail prescription data excludes Novo Nordisk's direct-to-consumer channels and telehealth platforms, suggesting actual demand could be double or triple the reported number, indicating a larger market opportunity.
- Clear Competitive Advantage: With distribution in over 70,000 retail locations, Novo Nordisk has established brand loyalty before Eli Lilly's oral competitor, Orforglipron, is set to launch in 2026, giving Novo a significant first-mover advantage.
- Industry Transformation Signal: The mainstream adoption of oral GLP-1 drugs could dramatically expand the total addressable market for weight-loss medications, altering revenue trajectories for both Novo and Lilly, with increasing market attention suggesting Wall Street may be underestimating the potential explosion in this sector.
Continue Reading
Amazon Launches Novo Nordisk's Wegovy Weight-Loss Pill with Monthly Costs Starting at $25
- Drug Launch: Amazon has introduced Novo Nordisk's Wegovy weight-loss pill through its digital pharmacy, with cash-paying patients facing a monthly cost starting at $149, while insured patients can access it for as low as $25, significantly lowering the barrier to obesity medication access and likely attracting more consumers.
- Market Expansion: The launch of the Wegovy pill marks Novo Nordisk's first oral GLP-1 drug release in the U.S., aiming to disrupt the dominance of traditional injectable medications and further expand its customer base while increasing market share.
- Strategic Partnerships: Since its launch in 2020, Amazon Pharmacy has collaborated with companies like WeightWatchers and Eli Lilly to deliver weight-loss medications, with analysts estimating annual revenue could reach $2 billion, thereby solidifying its position in the U.S. healthcare sector.
- Convenient Services: Amazon promises same-day prescription delivery for nearly half of U.S. consumers, and this strategy of rapid delivery and price transparency is expected to enhance user experience and attract more users to its pharmacy services.
Continue Reading